This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more comprehensive economic evaluation that could include novel elements of value (e.g., insurance value and equity) as part of either an “augmented” costeffectiveness analysis or a multicriteria decision analysis. Given an aggregation of elements to a measure of value...
BACKGROUND: Policymakers in high-, low-, and middle-income countries alike face challenging choices ...
Assessing the value for money offered by new health technologies is playing an increasingly importan...
The publications used in this thesis consist of eight first author publications (2008 to 2013) explo...
The fourth section of our Special Task Force report focuses on a health plan or payer’s technology a...
The fifth section of our Special Task Force report identifies and discusses two aggregation issues: ...
Cost-effectiveness models that present results in terms of cost per quality-adjusted life-year for h...
The economic evaluation of new health technologies to assess whether the value of the expected healt...
Contains fulltext : 169877.pdf (publisher's version ) (Open Access)Priority settin...
A growing number of health care systems internationally use formal economic evaluation methods to su...
ABSTRACT Introduction : Economic evaluations can provide "value-for money" information to ...
The economic evaluation of new health technologies to assess whether the value of the expected healt...
AbstractA growing number of jurisdictions now request economic data in support of their decision-mak...
OBJECTIVES: We highlight the importance of undertaking value assessments for health system inputs if...
Aim: This paper summarizes the deficiencies and weaknesses of the most frequently used methods for t...
Objectives: Despite the growing number of pharmacoeconomic (PE)/health economic (HE) studies, very l...
BACKGROUND: Policymakers in high-, low-, and middle-income countries alike face challenging choices ...
Assessing the value for money offered by new health technologies is playing an increasingly importan...
The publications used in this thesis consist of eight first author publications (2008 to 2013) explo...
The fourth section of our Special Task Force report focuses on a health plan or payer’s technology a...
The fifth section of our Special Task Force report identifies and discusses two aggregation issues: ...
Cost-effectiveness models that present results in terms of cost per quality-adjusted life-year for h...
The economic evaluation of new health technologies to assess whether the value of the expected healt...
Contains fulltext : 169877.pdf (publisher's version ) (Open Access)Priority settin...
A growing number of health care systems internationally use formal economic evaluation methods to su...
ABSTRACT Introduction : Economic evaluations can provide "value-for money" information to ...
The economic evaluation of new health technologies to assess whether the value of the expected healt...
AbstractA growing number of jurisdictions now request economic data in support of their decision-mak...
OBJECTIVES: We highlight the importance of undertaking value assessments for health system inputs if...
Aim: This paper summarizes the deficiencies and weaknesses of the most frequently used methods for t...
Objectives: Despite the growing number of pharmacoeconomic (PE)/health economic (HE) studies, very l...
BACKGROUND: Policymakers in high-, low-, and middle-income countries alike face challenging choices ...
Assessing the value for money offered by new health technologies is playing an increasingly importan...
The publications used in this thesis consist of eight first author publications (2008 to 2013) explo...